Trial Profile
A Randomized, Blinded, Placebo-controlled, Phase 1 Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adult Subjects, as Assessed by Fecal Bile Acid Excretion
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Maralixibat (Primary) ; Volixibat (Primary)
- Indications Alagille syndrome; Cholestasis; Intrahepatic cholestasis; Primary biliary cirrhosis; Primary sclerosing cholangitis
- Focus Therapeutic Use
- Sponsors Shire
- 13 Nov 2020 According to a Mirum Pharmaceuticals media release, data from this study featured at the Annual Meeting of the American Association for the Study of Liver Diseases - The Liver Meeting Digital Experience 2020.
- 13 Nov 2020 Results published in the Media Release
- 02 Nov 2020 According to a Mirum Pharmaceuticals media release, data from this trial will be presented in a poster presentation at The Liver Meeting Digital Experience™, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2020.